Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29

Rhea-AI Summary

Vaxart, Inc. (Nasdaq: VXRT) announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine & Immunotherapy Congress West Coast 2022 in San Diego on November 29, 2022. The presentation will focus on Vaxart’s Phase II trial results for its oral pill COVID-19 vaccine candidate, which recently showed positive top-line results. Vaxart specializes in developing oral recombinant vaccines and aims to create vaccines for various diseases, including COVID-19 and HPV.

News Market Reaction – VXRT

+1.49%

+1.49% Session move

In the trading session that priced this news, VXRT gained 1.49%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine & Immunotherapy Congress West Coast 2022 in San Diego on Tuesday, November 29, 2022 at 1:50 p.m. PT / 4:50 p.m. ET.

Dr. Tucker will provide an overview of Vaxart’s Phase II trial for its oral pill COVID-19 vaccine candidate.

Vaxart recently announced positive top-line Phase II clinical study results for its Wuhan S-only COVID-19 pill vaccine candidate.

About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza, and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contacts

Vaxart Media Relations:	Investor Relations:
Mark Herr	Andrew Blazier
Vaxart, Inc.	FINN Partners
mherr@vaxart.com	IR@Vaxart.com
(203) 517-8957	(646) 871-8486

FAQ

What will Vaxart present at the World Vaccine & Immunotherapy Congress West Coast on November 29, 2022?

Vaxart will present an overview of its Phase II trial for its oral pill COVID-19 vaccine candidate.

When are the Phase II clinical study results for Vaxart's COVID-19 vaccine candidate announced?

Vaxart announced positive top-line Phase II clinical study results recently before the World Vaccine & Immunotherapy Congress.

What is Vaxart's focus in vaccine development?

Vaxart focuses on developing oral recombinant vaccines for COVID-19, norovirus, seasonal influenza, respiratory syncytial virus (RSV), and HPV.

What are the key features of Vaxart's vaccine delivery platform?

Vaxart's platform allows vaccines to be administered via tablets that do not require refrigeration and eliminate needle-stick injury risks.

What is the ticker symbol for Vaxart?

The ticker symbol for Vaxart is VXRT.